ArticleInternational journal of molecular sciences2023

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.

Chung-Pu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.